How many banks in Malaysia are offering credit cards? | Updated

By Editorial Team -
  1. Maybank
  2. HSBC
  3. UOB
  4. CIMB
  5. Direct Access (under CIMB)
  6. RHB
  7. Citibank
  8. EonBank (under Hong Leong)
  9. Alliance
  10. Public Bank
  11. Affin Bank
  12. Hong Leong
  13. Standard Chartered
  14. OCBC
  15. AmBank
  16. MBF (under Ambank)
  17. Bank Islam
  18. Aeon
  19. BSN
  20. Bank Rakyat

Comments

Post a Comment

Pages

Popular posts from this blog

Did Steve Jobs Refuse Treatment for Pancreatic Cancer?

By Editorial Team -
Image
On October 5, 2011, Steve Jobs died after a battle with a rare pancreatic cancer at age 56. But he may have lived longer if he sought proper medical care in time. When Apple co-founder Steve Jobs was first diagnosed with pancreatic cancer in 2003, his doctors advised him to seek surgery as soon as possible. Instead, he delayed the procedure for nine months and attempted to treat himself with alternative medicine. This fateful decision may have quickened Steve Jobs’ death — when he still could’ve been saved. Steve Jobs died from pancreatic cancer complications on October 5, 2011, just eight years after his initial diagnosis. He was only 56 years old when he died, but his cancer had taken such a toll on his body that he looked gaunt, frail, and much older than his actual age. It was a far cry from the robust, energetic man who had once pioneered the personal computer era.    ...
Read more

Top 10 Healthcare Companies by Revenue in 2025

By Editorial Team -
Image
Here are the top 10 healthcare companies by revenue as of 2024-2025, primarily based on trailing twelve-month (TTM) and fiscal year 2024 revenue data from multiple sources: 1. UnitedHealth Group Inc. Revenue: Approximately $379.5 billion to $410 billion Description: A leading health insurance company providing data analytics, consulting, and pharmacy care services. Market: NYSE, USA ( 1 ,  2 ,  4 ) 2. CVS Health Corp. Revenue: Around $361 billion to $373 billion Description: A major pharmacy benefits manager and health services provider. Market: NYSE, USA ( 1 ,  2 ,  4 ) 3. McKesson Corp. Revenue: About $309 billion to $359 billion Description: A global pharmaceutical distribution and healthcare services company. Market: NYSE, USA ( 1 ,  2 ,  4 ) 4. Cencora (formerly AmerisourceBergen) Revenue: Approximately $294 billion to $310 billion Description: A pharmaceutical sourcing and distribution services company. Market: NYSE, USA ( 2 ,  4 ) 5. Cardinal He...
Read more

Top 10 Pharmaceutical Companies by Revenue in 2025

By Editorial Team -
Image
Here are the top 10 pharmaceutical companies by revenue as of 2025, primarily based on first quarter 2025 revenue data. Only one of the top 10 drugmakers, Eli Lilly, is expected to achieve a double-digit revenue increase by the end of 2025. Eli Lilly is projecting a robust growth of around 32% in 2025 compared to 2024, driven by strong sales of its diabetes and weight-loss drugs such as Mounjaro and Zepbound, with full-year revenue guidance between $58 billion and $61 billion ( 1 ,  2 ,  3 ). In contrast, most of the other top 10 pharmaceutical companies are expected to see more moderate revenue growth, generally in the range of 6% to 9% by the end of 2025. This reflects steady but less dramatic expansion compared to Eli Lilly’s exceptional performance ( 4 ). Lilly—boosted by sales of its diabetes and obesity drugs Moujaro and Zepbound— projects  its sales to fall between $58 billion and $61 billion. At the midpoint of the projection, it would be a 32% increase, matching ...
Read more

Top 10 Most Anticipated Drug Launches of 2025

By Editorial Team -
Image
Biopharma may soon be in for a blockbuster boom. In the latest edition of its annual ranking of the biggest potential drug launches of the coming year, Evaluate listed 10 drugs that are slated to earn approvals in 2025. According to the analysts’ forecasts, all together, the meds stand to generate a whopping $29 billion in annual sales by the end of the decade. That’s nearly double the estimate for last year’s top 10 . In that case, Evaluate calculated a conservative $15.2 billion in 2028 sales for 2024’s biggest expected launches, which included the likes of Bristol Myers Squibb’s schizophrenia drug Cobenfy , Eli Lilly’s Alzheimer’s disease med Kisunla and Madrigal Pharmaceuticals’ MASH treatment Rezdiffra in the top three—all of which were indeed approved throughout last year. In fact, 2025’s total is the highest in the last five years, topping even Evaluate’s high-flying forecast for 2022, when the analysts estimated total 2026 sales of $26.9 billion for the year’s  most anti...
Read more

Glutathione vs NAD: What's the Difference?

By Editorial Team -
Image
What's the difference between glutathione and NAD? We will cover the essentials and explain about each of these nutrients below.  What is Glutathione? Glutathione or GSH (tripeptide of glutamic acid, cysteine, and glycine) is referred to as the body’s “master antioxidant” or the “mother of all antioxidants” because it is your body’s primary and most prevalent protector, found in all mammalian tissue. Types of Glutathione There is a lot of confusion about GSH and what makes an effective glutathione supplement. There are different types, different formulas, and a lot of different companies saying different things. L-Glutathione or Reduced Glutathione because it is the most commonly found, least expensive, and the true core behind other forms you will find. There is some debate whether L-Glutathione alone can be effective taken orally. The theory being the enzymes in your stomach break it down before it can ever reach the blood stream and become useful. Some  evidence ...
Read more

Top 10 Drugs Losing US Exclusivity in 2025

By Editorial Team -
Image
Summary 1. Stelara: 2024 U.S. sales: $6.72 billion 2. Eylea: 2024 U.S. sales: $4.77 billion 3. Prolia/Xgeva: 2024 U.S. sales: $4.39 billion 4. Entresto: 2024 U.S. sales: $4.05 billion 5. Soliris: 2024 U.S. sales: $1.52 billion 6. Promacta: 2024 U.S. sales: $1.18 billion 7. Simponi/Simponi Aria: 2024 U.S. sales: $1.08 billion 8. Tysabri: 2024 U.S. sales: $920 million 9. Tasigna: 2024 U.S. sales: $848 million 10. Brilinta: 2024 U.S. sales: $751 million Introduction While the pharmaceutical industry routinely faces high-profile losses of exclusivity each year, this year's list is particularly notable. Johnson & Johnson’s Stelara is already contending with several biosimilars, with more expected throughout the year. With $6.72 billion in U.S. sales projected for 2024, Stelara represents the largest U.S. loss of exclusivity since AbbVie’s Humira patent cliff in early 2023. Although Johnson & Johnson had anticipated a “late 2023” patent expiration, the company extended Stelara’s ...
Read more

Top 10 Pharma Companies by Market Cap in 2025

By Editorial Team -
Image
Here are the top 10 pharmaceutical companies by market cap as of July 2025. Only one of the top 10 drugmakers, Eli Lilly, is expected to achieve a double-digit revenue increase by the end of 2025. Eli Lilly is projecting a robust growth of around 32% in 2025 compared to 2024, driven by strong sales of its diabetes and weight-loss drugs such as Mounjaro and Zepbound, with full-year revenue guidance between $58 billion and $61 billion ( 1 ,  2 ,  3 ). In contrast, most of the other top 10 pharmaceutical companies are expected to see more moderate revenue growth, generally in the range of 6% to 9% by the end of 2025. This reflects steady but less dramatic expansion compared to Eli Lilly’s exceptional performance ( 4 ). Credit: CompaniesMarketCap.com Lilly—boosted by...
Read more

Top 10 Pharma Companies by R&D Spend 2024

By Editorial Team -
Image
In 2024, the pharmaceutical industry witnessed significant shifts in research and development (R&D) investments, with companies like Merck & Co. and AstraZeneca making notable strategic decisions that impacted their positions among top R&D spenders. The average cost for major pharmaceutical companies to develop a drug in 2024 rose to $2.23 billion, up from $2.12 billion the previous year. This increase reflects the growing complexity and expense associated with bringing new therapies to market. ​( Fierce Biotech ) These developments illustrate the dynamic nature of R&D investments in the pharmaceutical sector, influenced by strategic partnerships, acquisitions, and the escalating costs of drug development. 1. Merck & Co. R&D SPENDING 2024: $17.9 billion Change from 2023: -41% Total 2024 revenue: $64.2 billion R&D budget as percentage of revenue: 28% Market capitalisation: 198.3 B USD (as of June 2025) Merck & Co.’s R&D spending plummeted from the d...
Read more

7 Best Crypto Exchanges Malaysia 2025

By Editorial Team -
Image
If you're looking for the best cryptocurrency exchanges in Malaysia in 2025, it's important to choose platforms that are secure and fully compliant with local regulations. In Malaysia, Digital Asset Exchanges (DAX) are regulated and licensed by the Securities Commission Malaysia (SC), which ensures they meet strict standards for investor protection and legal compliance. Luno, Binance, Sinegy, Tokenize Exchange, MX Global, Hata and Torum are popular choices. The best cryptocurrency exchanges work similarly to the best stock trading apps, offering competitive fees and resources on digital marketplaces like mobile or desktop. Crypto enthusiasts can easily buy, sell, and store popular digital currencies like Bitcoin or altcoins like Ethereum. Note that if you don't want to use your exchange's built-in wallet (if applicable), you'll need to set up an external crypto wallet, to store your assets securely. Here are details of cryptocurrency exchanges you can use to buy Bit...
Read more

Top 10 Drugs by Worldwide Sales in 2024

By Editorial Team -
Image
It's been several years since COVID-19 vaccines from Pfizer and Moderna jumped to the top of the pharma industry's sales charts, displacing longtime stalwarts with unprecedented sales. But, as 2023 featured major patent expirations, the rise of weight loss drugs and other new dynamics, the year’s ranking of the top 10 drugs by global sales featured its fair share of surprises. Merck’s oncology king Keytruda rose to the top last year, adding yet another feather in its cap. With more than 30 indications across various cancer types and stages, the PD-L1 inhibitor shows no signs of stopping. With $25 billion in global sales, the drug accounted for about 40% of Merck’s total revenue last year. Keytruda's sales are expected to reach $30 billion this year. Keytruda had previously fallen right behind AbbVie's Humira, which held the title of the world’s bestselling drug for nine years in a row until Pfizer and BioNTech’s Comirnaty knocked AbbVie’s Humira off its perch in 2021. N...
Read more